Clinical Pharmacokinetics of Paclitaxel

[1]  M. Egorin,et al.  Effect of cimetidine, probenecid, and ketoconazole on the distribution, biliary secretion, and metabolism of [3H]taxol in the Sprague-Dawley rat. , 1994, Drug metabolism and disposition: the biological fate of chemicals.

[2]  J J Shuster,et al.  Saturable pharmacokinetics and paclitaxel pharmacodynamics in children with solid tumors. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  S. Arbuck.  Paclitaxel: what schedule? What dose? , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  J. Schiller,et al.  Phase I trial of 3-hour infusion of paclitaxel with or without granulocyte colony-stimulating factor in patients with advanced cancer. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  S. Howell,et al.  Synergistic interaction between cisplatin and taxol in human ovarian carcinoma cells in vitro. , 1994, British Journal of Cancer.

[6]  K. Cowan,et al.  Pharmacokinetics of taxol and doxorubicin administered alone and in combination by continuous 72-hour infusion. , 1994, Journal of the National Cancer Institute.

[7]  B. Monsarrat,et al.  Taxol metabolism by human liver microsomes: identification of cytochrome P450 isozymes involved in its biotransformation. , 1994, Cancer research.

[8]  C. Lipschultz,et al.  Cytotoxic studies of paclitaxel (Taxol) in human tumour cell lines. , 1993, British Journal of Cancer.

[9]  M. Relling,et al.  Phase I trial of paclitaxel in children with refractory solid tumors: a Pediatric Oncology Group Study. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  J. McMillan,et al.  Taxol metabolism in rat hepatocytes. , 1993, Biochemical pharmacology.

[11]  A. C. Dubbelman,et al.  Pharmacokinetics of paclitaxel and metabolites in a randomized comparative study in platinum-pretreated ovarian cancer patients. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  James B. Mitchell,et al.  Taxol in combination with doxorubicin or etoposide possible antagonism in vitro , 1993, Cancer.

[13]  P. Goodman,et al.  Phase I pharmacokinetic study of cyclosporin A combined with doxorubicin. , 1993, Cancer research.

[14]  E K Rowinsky,et al.  Phase I and pharmacologic study of paclitaxel and cisplatin with granulocyte colony-stimulating factor: neuromuscular toxicity is dose-limiting. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  E. Eisenhauer,et al.  Clinical toxicities encountered with paclitaxel (Taxol). , 1993, Seminars in oncology.

[16]  F. Loor,et al.  Restoration of taxol sensitivity of multidrug-resistant cells by the cyclosporine SDZ PSC 833 and the cyclopeptolide SDZ 280-446. , 1993, Journal of the National Cancer Institute.

[17]  P. Schiff,et al.  Characterization of polyclonal and monoclonal anti-taxol antibodies and measurement of taxol in serum. , 1993, Cancer research.

[18]  P. Grothaus,et al.  An enzyme immunoassay for the determination of taxol and taxanes in Taxus sp. tissues and human plasma. , 1993, Journal of immunological methods.

[19]  R. Barakat,et al.  Phase I trial of intraperitoneal taxol: a Gynecoloic Oncology Group study. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  E. Hall,et al.  Taxol sensitizes human astrocytoma cells to radiation. , 1992, Cancer research.

[21]  E K Rowinsky,et al.  Sequences of taxol and cisplatin: a phase I and pharmacologic study. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  J. Koeller,et al.  A phase I trial of taxol given by a 6-hour intravenous infusion. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  V. Stella,et al.  Stability, compatibility, and plasticizer extraction of taxol (NSC-125973) injection diluted in infusion solutions and stored in various containers. , 1991, American journal of hospital pharmacy.

[24]  B. Monsarrat,et al.  Taxol metabolism. Isolation and identification of three major metabolites of taxol in rat bile. , 1990, Drug metabolism and disposition: the biological fate of chemicals.

[25]  R. Donehower,et al.  Taxol: a novel investigational antimicrotubule agent. , 1990, Journal of the National Cancer Institute.

[26]  R. Donehower,et al.  Development of polyploidization in taxol-resistant human leukemia cells in vitro. , 1990, Cancer research.

[27]  D. Ettinger,et al.  Phase I and pharmacodynamic study of taxol in refractory acute leukemias. , 1989, Cancer research.

[28]  R. Donehower,et al.  Microtubule changes and cytotoxicity in leukemic cell lines treated with taxol. , 1988, Cancer research.

[29]  J. Willson,et al.  Phase I study of taxol administered as a short i.v. infusion daily for 5 days. , 1987, Cancer treatment reports.

[30]  R. Lipton,et al.  Phase I trial of taxol given as a 24-hour infusion every 21 days: responses observed in metastatic melanoma. , 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  R. Lipton,et al.  Phase I clinical and pharmacokinetic study of taxol. , 1987, Cancer research.

[32]  R. Simon,et al.  Tolerance to antineoplastic agents in children and adults. , 1985, Cancer treatment reports.

[33]  J. Manfredi,et al.  Taxol binds to cellular microtubules , 1982, The Journal of cell biology.

[34]  D. Kingston,et al.  Structure-activity study of cytotoxicity and microtubule assembly in vitro by taxol and related taxanes. , 1982, Biochemical and biophysical research communications.

[35]  J. Willson,et al.  Inhibition of human ovarian cancer colony formation by adriamycin and its major metabolites. , 1980, Cancer research.

[36]  P. Schiff,et al.  Promotion of microtubule assembly in vitro by taxol , 1979, Nature.

[37]  G. Bonadonna,et al.  Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationships in humans. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  James B. Mitchell,et al.  Taxol in Combination with Doxorubicin or Etoposide , 1993 .

[39]  B. Monsarrat,et al.  Hepatic metabolism and biliary excretion of Taxol in rats and humans. , 1993, Journal of the National Cancer Institute. Monographs.

[40]  M. Brecher,et al.  Cremophor-EL enhances taxol efficacy in a multi-drug resistant C1300 neuroblastoma cell line. , 1993, Anticancer research.

[41]  D. V. Von Hoff,et al.  Analysis of anticancer drugs in biological fluids: determination of taxol with application to clinical pharmacokinetics. , 1990, Journal of pharmaceutical and biomedical analysis.

[42]  L. Grochow,et al.  High-performance liquid chromatographic assay for taxol in human plasma and urine and pharmacokinetics in a phase I trial. , 1987, Cancer treatment reports.